2,4-diaminopyrimidine has been researched along with Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, M; Liu, N; Lv, R; Qin, Q; Sun, Y; Wang, R; Wu, T; Yin, W; Zhang, C; Zhao, D | 1 |
| Aimone, LD; Albom, MS; Angeles, TS; Brown, RA; Dorsey, BD; Galinis, D; Grobelny, JV; Herbertz, T; Husten, J; Kocsis, LS; LoSardo, C; Miknyoczki, SJ; Murthy, S; Rolon-Steele, D; Theroff, JP; Underiner, TL; Wells-Knecht, KJ; Worrell, CS; Zeigler, KS; Zificsak, CA | 1 |
| Aimone, LD; Albom, MS; Angeles, TS; Cheng, M; Dorsey, BD; Mesaros, EF; Ott, GR; Quail, MR; Theroff, JP; Underiner, TL; Wan, W; Zificsak, CA | 1 |
3 other study(ies) available for 2,4-diaminopyrimidine and Neoplasms
| Article | Year |
|---|---|
Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2,4-diaminopyrimidine scaffold.
Topics: Antineoplastic Agents; Drug Design; Humans; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Receptor, trkA; Structure-Activity Relationship | 2022 |
2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Humans; Mice; Mice, Nude; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Xenograft Model Antitumor Assays | 2011 |
Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors.
Topics: Administration, Oral; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Cyclohexylamines; Enzyme Activation; Enzyme Inhibitors; Infusion Pumps; Inhibitory Concentration 50; Mice; Molecular Structure; Neoplasms; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2011 |